Becton Dickinson Reports Q2 2025 Earnings with Revenue Growth and Margin Improvements
Becton Dickinson (BDX) reported Q2 2025 earnings with a 6% revenue increase, though Life Sciences underperformed due to reduced research funding. Adjusted gross and operating margins improved, and adjusted diluted EPS rose 5.7%, but full-year organic growth guidance was lowered to 3%-3.5% due to ongoing market pressures.
Tickers: $BDX
Topics: adjusted gross margin capital deployment EPS growth operating margin revenue growth tariff impact